Hidden fracture risks: GLP-1 weight loss drugs accelerate BONE LOSS
By ljdevon // 2026-03-23
Copy
 
The multi-billion dollar weight loss drug revolution, built on glucagon-like peptide-1 receptor agonists (GLP-1Ra), has been marketed as a metabolic breakthrough for the nearly 900 million adults worldwide living with obesity. But buried beneath the headlines of dramatic weight reduction and cardiovascular benefits lies a troubling clinical reality that patients and prescribing physicians were never fully warned about: these drugs are quietly dismantling bone architecture, accelerating bone turnover that favors resorption over formation, and may be setting up a significant portion of the millions taking these medications for an increased fracture risk that industry-sponsored trials conveniently failed to emphasize. Key points:
  • Semaglutide users in the SELECT cardiovascular outcomes study experienced a five-fold higher rate of hip and pelvic fractures compared to placebo recipients among female participants.
  • GLP-1Ra cause bone mineral density reductions of 2.1 percent at the lumbar spine and 2.6 percent at the total hip within one year of treatment.
  • These drugs create bone metabolism changes that mirror the detrimental effects of extreme calorie restriction and bariatric surgery.
  • Pre-clinical studies showing positive bone effects used drug concentrations far exceeding approved human doses.
  • Current evidence reveals the drugs increase CTX, a marker of bone resorption, by nearly 55 percent while offering no corresponding increase in bone formation markers.

Weight loss at the expense of skeletal integrity

The mechanisms underlying GLP-1Ra’s effect on bone are only now coming into focus, and the picture is far from reassuring. A comprehensive review published in Osteoporosis International examining data from January 2013 through December 2024 found that these medications, including liraglutide (Saxenda) and semaglutide (Wegovy), produce skeletal changes that closely mirror the detrimental bone effects observed with extreme calorie restriction¹. The review documented that significant weight reduction of approximately 7 to 10 percent through calorie restriction results in high turnover bone loss, and GLP-1Ra appear to induce similar, if not identical, pathological mechanisms. In a 52-week randomized controlled trial involving participants with elevated fracture risk, those receiving semaglutide experienced a 54.8 percent greater increase in CTX, a marker indicating bone resorption is outpacing formation, compared to the placebo group¹. The same study revealed alarming declines in bone mineral density: a 2.1 percent reduction at the lumbar spine and a 2.6 percent reduction at the total hip. These are not negligible numbers for a patient population already potentially predisposed to skeletal fragility. The preclinical research that initially suggested GLP-1Ra might benefit bone health requires careful scrutiny. While rodent studies showed liraglutide positively influenced bone material properties, these effects were observed at concentrations “much higher than those approved for human obesity treatment,” according to the Osteoporosis International review¹. In simpler terms, the positive bone effects seen in animal models occurred at drug levels that would never be administered to human patients, leaving clinicians with only the detrimental weight-loss-associated bone loss as the dominant clinical effect.

Industry data reveals fractures, but questions remain unanswered

Perhaps the most damning evidence emerges from the SELECT study, a cardiovascular outcomes trial sponsored by Novo Nordisk that enrolled 17,604 individuals aged 45 years and older with existing cardiovascular disease and a body mass index exceeding 27 kg/m². While the study’s primary findings touted a 20 percent reduction in major adverse cardiovascular events, critical safety data disclosed in 2025 painted a different picture for skeletal health. Among female patients receiving semaglutide, the rate of hip and pelvic fractures reached 1.0 percent, compared to just 0.2 percent in the placebo group¹. For participants aged 75 years and above, fracture rates climbed to 2.4 percent in the treatment group versus 0.6 percent in the placebo group. These represent a five-fold and four-fold increased risk, respectively, yet the study’s primary publication failed to highlight these findings, requiring separate disclosure elsewhere¹. The implications are particularly concerning given the demographic profile of GLP-1 users. Real-world data from France’s early-access program for semaglutide 2.4 mg revealed that of 6,990 patients who began treatment, 65.8 percent were female, with a median age of 49 years, and 11.3 percent were aged 65 years or older¹. This population, predominantly women in perimenopausal and postmenopausal age ranges, faces the highest baseline risk for osteoporosis and fragility fractures. Researchers have noted that the bone metabolism changes induced by GLP-1Ra extend beyond simple mineral density loss. The substantial weight reduction these drugs produce inevitably leads to lean mass loss, raising concerns about osteosarcopenia, the combination of bone loss and muscle wasting that dramatically increases fall-related fracture risk¹. A separate review in Current Reviews in Musculoskeletal Medicine noted that while GLP-1RAs appear to preserve skeletal muscle function despite lean mass loss, the heterogeneity in findings underscores the need for further long-term investigation². The unanswered questions are mounting. What happens to bone micro-architecture after two or three years of continuous GLP-1 use? How do these drugs affect fracture risk in postmenopausal women who represent the majority of users? What interventions, if any, can mitigate the bone resorption these drugs trigger? The Osteoporosis International review concluded that “further research is needed to explore the effects of GLP-1Ra on bone metabolism and fracture-related outcomes”¹, a statement that should give pause to the millions currently prescribed these medications without adequate long-term safety data. Source include: Pubmed.gov (Osteoporos Int. 2025 Sep 8;36(11):2115–2126. doi: 10.1007/s00198-025-07664-1) Pubmed.gov (Curr Rev Musculoskelet Med. 2025; doi: 10.1007/s12178-025-09978-3) TheEpochTimes.com
Copy